SCHEMBL6989980

SCHEMBL6989980

COC1=CNS(=O)(=O)c2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.43
LMNA P02545 3/20 0.43
USP2 O75604 2/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
BCHE P06276 1/20 0.43
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43
CA5A P35218 1/20 0.43
CA7 P43166 1/20 0.43
KMT2A Q03164 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
CA5B Q9Y2D0 1/20 0.43
SLC40A1 Q9NP59 3/20 0.41
ALPI P09923 3/20 0.40
ALPL P05186 2/20 0.40
ALDH1A1 P00352 4/20 0.39
HPGD P15428 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8904247 0.72 KDM4E (0.47) KDM4ELMNAUSP2CA12CA1
SCHEMBL8795307 0.72 MAPT (0.56) KDM4ELMNAUSP2KMT2AALDH1A1
SCHEMBL25716769 0.71 KDM4E (0.43) KDM4ELMNAUSP2CA12CA1
Saccharin SCHEMBL699319 0.67 CA12 (0.85) KDM4ELMNAUSP2CA12CA1
SCHEMBL18535393 0.65 GPR3 (0.59) KDM4ELMNAUSP2CA12CA1
SCHEMBL7404812 0.62 KDM4E (0.54) KDM4ELMNAUSP2CA12CA1
Saccharin SCHEMBL27961842 0.62 CA12 (0.92) KDM4ELMNAUSP2CA12CA1
Saccharin SCHEMBL2638829 0.60 CA12 (0.88) KDM4ELMNAUSP2CA12CA1
Saccharin SCHEMBL27848168 0.60 CA12 (0.88) KDM4ELMNAUSP2CA12CA1
SCHEMBL27047101 0.60 KDM4E (0.57) KDM4ELMNAUSP2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6664251-B2 Serotonin receptor antagonist; treating cardiovascular disorder DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2003-12-16 US disclosed
EP-0686632-B1 BENZOTHIAZINE DERIVATIVE DAIICHI SUNTORY PHARMA CO LTD (JP) 2003-08-06 EP disclosed
US-20030078256-A1 Benzothiazine derivative SUNTORY LIMITED (JP) 2003-04-24 US disclosed
US-6316442-B1 TREATMENT OF HEART DISEASE AND CEREBROVASCULAR DISTURBANCES SUNTORY LIMITED (JP) 2001-11-13 US disclosed
US-6001827-A Benzothiazine derivative SUNTORY LIMITED (JP) 1999-12-14 US disclosed
US-5874429-A ANTIISCHEMIC AGENTS; CEREBROVASCULAR DISORDERS; CIRCULATORY IDSORDERS SUNTORY LIMITED (JP) 1999-02-23 US disclosed
EP-0686632-A1 BENZOTHIAZINE DERIVATIVE SUNTORY LIMITED (JP) 1995-12-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078256-A1 Benzothiazine derivative TPH2, ADRB2, TPH1 KDM4E 2400/4885LMNA 376/4885USP2 3294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.